Patent · US Active

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

USRE49353E1 · kind E1 · reissue

0Cited by
103References
48Claims
0Family size

Assignee

Inventor

Key dates

Filing dateAug 20, 2020
Grant dateJan 3, 2023
Priority date
Expiry dateAug 20, 2040

Classification

  • Technology area (CPC —)General

Abstract

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.